Koen Mertens
Research Subjects
Koen Mertens has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Alexander B. Meijer
Molecular and Cellular Hemostasis, Sanquin Research, 1066 CX Amsterdam, The Netherlands
3 shared publications- Jan Voorberg
Department of Molecular Hematology, Sanquin Research, Amsterdam, The Netherlands
3 shared publications Maartje van Den Biggelaar
Molecular and Cellular Hemostasis, Sanquin Research, 1066 CX Amsterdam, The Netherlands
3 shared publicationsEduard H.T.M. Ebberink
Molecular and Cellular Hemostasis, Sanquin Research, 1066 CX Amsterdam, The Netherlands
2 shared publicationsH. J. M. Brinkman
Department of Plasma Proteins, Sanquin Research, Amsterdam
2 shared publicationsI. Dienava‐Verdoold
Department of Plasma Proteins, Sanquin Research, Amsterdam
2 shared publications
Latest Publications
- Open Access
- 9 March 2021
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 19 (6) , 1447-1459
Probing activation‐driven changes in coagulation factor IX by mass spectrometry
- 9 March 2021
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 19 (6) , 1447-1459
Open AccessProbing activation‐driven changes in coagulation factor IX by mass spectrometry
- 3 December 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (23) , 2703-2714
Factor VIII–driven changes in activated factor IX explored by hydrogen-deuterium exchange mass spectrometry
The assembly of the enzyme-activated factor IX (FIXa) with its cofactor, activated factor VIII (FVIIIa) is a crucial event in the coagulation cascade. The absence or dysfunction of either enzyme or cofactor severely compromises hemostasis and causes hemophilia. FIXa is a notoriously inefficient enzyme that needs FVIIIa to drive its hemostatic potential, by a mechanism that has remained largely elusive to date. In this study, we employed hydrogen–deuterium exchange-mass spectrometry (HDX-MS) to investigate how FIXa responds to assembly with FVIIIa in the presence of phospholipids. This revealed a complex pattern of changes that partially overlaps with those changes that occur upon occupation of the substrate-binding site by an active site-directed inhibitor. Among the changes driven by both cofactor and substrate, HDX-MS highlighted several surface loops that have been implicated in allosteric networks in related coagulation enzymes. Inspection of FVIIIa-specific changes indicated that 3 helices are involved in FIXa–FVIIIa assembly. These are part of a basic interface that is also known as exosite II. Mutagenesis of basic residues herein, followed by functional studies, identified this interface as an extended FVIIIa-interactive patch. HDX-MS was also applied to recombinant FIXa variants that are associated with severe hemophilia B. This revealed that single amino acid substitutions can silence the extended network of FVIIIa-driven allosteric changes. We conclude that HDX-MS has the potential to visualize the functional impact of disease-associated mutations on enzyme–cofactor complexes in the hemostatic system.
- 3 December 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (23) , 2703-2714
Factor VIII–driven changes in activated factor IX explored by hydrogen-deuterium exchange mass spectrometry
The assembly of the enzyme-activated factor IX (FIXa) with its cofactor, activated factor VIII (FVIIIa) is a crucial event in the coagulation cascade. The absence or dysfunction of either enzyme or cofactor severely compromises hemostasis and causes hemophilia. FIXa is a notoriously inefficient enzyme that needs FVIIIa to drive its hemostatic potential, by a mechanism that has remained largely elusive to date. In this study, we employed hydrogen–deuterium exchange-mass spectrometry (HDX-MS) to investigate how FIXa responds to assembly with FVIIIa in the presence of phospholipids. This revealed a complex pattern of changes that partially overlaps with those changes that occur upon occupation of the substrate-binding site by an active site-directed inhibitor. Among the changes driven by both cofactor and substrate, HDX-MS highlighted several surface loops that have been implicated in allosteric networks in related coagulation enzymes. Inspection of FVIIIa-specific changes indicated that 3 helices are involved in FIXa–FVIIIa assembly. These are part of a basic interface that is also known as exosite II. Mutagenesis of basic residues herein, followed by functional studies, identified this interface as an extended FVIIIa-interactive patch. HDX-MS was also applied to recombinant FIXa variants that are associated with severe hemophilia B. This revealed that single amino acid substitutions can silence the extended network of FVIIIa-driven allosteric changes. We conclude that HDX-MS has the potential to visualize the functional impact of disease-associated mutations on enzyme–cofactor complexes in the hemostatic system.
- Open Access
- 5 January 2017
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 102 (4) , 686-694
Factor VIII/V C-domain swaps reveal discrete C-domain roles in factor VIII function and intracellular trafficking
Factor VIII C-domains are believed to contain specific function in co-factor activity and in interaction with von Willebrand factor. We have previously shown that factor VIII is co-targeted with von Willebrand factor to the Weibel-Palade bodies in blood outgrowth endothelial cells, even when factor VIII carries mutations in the light chain that are associated with defective von Willebrand factor binding. In this study we furthermore addressed the contribution of individual factor VIII C-domains in intracellular targeting, von Willebrand factor binding and co-factor activity by factor VIII/V C-domain swapping. Blood outgrowth endothelial cells were transduced with lentivirus encoding factor V, VIII and YFP-tagged C-domain chimeras, and examined by confocal microscopy. The same chimeras were produced in HEK293-cells for in vitro characterization and chemical foot-printing by mass spectrometry. In contrast to factor VIII, V did not target to Weibel-Palade bodies. The chimeras showed reduced Weibel-Palade body targeting, suggesting that this requires the factor VIII C1-C2 region. The factor VIII/V-C1 chimera did not bind von Willebrand Factor and had reduced affinity for factor IXa whereas the factor VIII/V-C2 chimera showed a small reduction in von Willebrand factor binding and normal interaction with factor IXa. This suggests that mainly the C1-domain carries factor VIII-specific features in assembly with von Willebrand Factor and factor IXa. Foot-printing analysis of the chimeras revealed increased exposure of lysine residues in the A1/C2- and C1/C2-domain interface, suggesting increased C2-domain mobility, which disrupts the natural C-domain tandem pair orientation. This affects intracellular trafficking more than extracellular function.
- 5 January 2017
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 102 (4) , 686-694
Open AccessFactor VIII/V C-domain swaps reveal discrete C-domain roles in factor VIII function and intracellular trafficking
Factor VIII C-domains are believed to contain specific function in co-factor activity and in interaction with von Willebrand factor. We have previously shown that factor VIII is co-targeted with von Willebrand factor to the Weibel-Palade bodies in blood outgrowth endothelial cells, even when factor VIII carries mutations in the light chain that are associated with defective von Willebrand factor binding. In this study we furthermore addressed the contribution of individual factor VIII C-domains in intracellular targeting, von Willebrand factor binding and co-factor activity by factor VIII/V C-domain swapping. Blood outgrowth endothelial cells were transduced with lentivirus encoding factor V, VIII and YFP-tagged C-domain chimeras, and examined by confocal microscopy. The same chimeras were produced in HEK293-cells for in vitro characterization and chemical foot-printing by mass spectrometry. In contrast to factor VIII, V did not target to Weibel-Palade bodies. The chimeras showed reduced Weibel-Palade body targeting, suggesting that this requires the factor VIII C1-C2 region. The factor VIII/V-C1 chimera did not bind von Willebrand Factor and had reduced affinity for factor IXa whereas the factor VIII/V-C2 chimera showed a small reduction in von Willebrand factor binding and normal interaction with factor IXa. This suggests that mainly the C1-domain carries factor VIII-specific features in assembly with von Willebrand Factor and factor IXa. Foot-printing analysis of the chimeras revealed increased exposure of lysine residues in the A1/C2- and C1/C2-domain interface, suggesting increased C2-domain mobility, which disrupts the natural C-domain tandem pair orientation. This affects intracellular trafficking more than extracellular function.
- 1 May 2012
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 10 (5) , 859-866
Factor seven activating protease (FSAP): does it activate factor VII?
- 1 May 2012
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 10 (5) , 859-866
Factor seven activating protease (FSAP): does it activate factor VII?
- 1 April 2011
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 9 (4) , 738-747
Patient‐derived monoclonal antibodies directed towards beta2 glycoprotein‐1 display lupus anticoagulant activity
- 1 April 2011
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 9 (4) , 738-747
Patient‐derived monoclonal antibodies directed towards beta2 glycoprotein‐1 display lupus anticoagulant activity
- Open Access
- 1 November 2007
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 5 (11) , 2235-2242
Requirements for cellular co‐trafficking of factor VIII and von Willebrand factor to Weibel–Palade bodies
- 1 November 2007
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 5 (11) , 2235-2242
Open AccessRequirements for cellular co‐trafficking of factor VIII and von Willebrand factor to Weibel–Palade bodies
- Open Access
- 1 June 2005
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 3 (6) , 1257-1265
The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor
- 1 June 2005
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 3 (6) , 1257-1265
Open AccessThe B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor
- 1 March 2005
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 3 (3) , 522-530
Does activated protein C-resistant factor V contribute to thrombin generation in hemophilic plasma?
- 1 March 2005
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 3 (3) , 522-530
Does activated protein C-resistant factor V contribute to thrombin generation in hemophilic plasma?
- 27 July 2004
- Published by Wiley in British Journal of Haematology
- Vol. 126 (5) , 722-725
Clearance of coagulation factor VIII in very low-density lipoprotein receptor knockout mice
- 27 July 2004
- Published by Wiley in British Journal of Haematology
- Vol. 126 (5) , 722-725
Clearance of coagulation factor VIII in very low-density lipoprotein receptor knockout mice